Goldman Sachs Group Inc. Buys 12,263 Shares of KalVista Pharmaceuticals, Inc. $KALV

Goldman Sachs Group Inc. raised its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 3.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 339,936 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,263 shares during the quarter. Goldman Sachs Group Inc. owned 0.68% of KalVista Pharmaceuticals worth $3,923,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. lifted its position in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of KalVista Pharmaceuticals by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after buying an additional 43,355 shares during the period. Woodline Partners LP increased its stake in shares of KalVista Pharmaceuticals by 25.5% during the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock valued at $18,666,000 after buying an additional 329,068 shares during the period. Emerald Advisers LLC increased its stake in shares of KalVista Pharmaceuticals by 7.4% during the first quarter. Emerald Advisers LLC now owns 898,190 shares of the specialty pharmaceutical company’s stock valued at $10,365,000 after buying an additional 62,140 shares during the period. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the first quarter valued at approximately $8,698,000.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,942 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider owned 119,841 shares in the company, valued at $1,584,298.02. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the firm’s stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the transaction, the chief executive officer owned 369,595 shares of the company’s stock, valued at $5,798,945.55. This represents a 8.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,835 shares of company stock valued at $892,350 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on KALV shares. JMP Securities boosted their target price on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday, September 12th. HC Wainwright boosted their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Finally, Leerink Partners upped their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, July 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $26.43.

KalVista Pharmaceuticals Stock Down 0.9%

NASDAQ KALV opened at $13.38 on Thursday. The stock’s 50-day moving average price is $14.03 and its 200-day moving average price is $12.84. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28. The company has a market capitalization of $675.96 million, a P/E ratio of -3.40 and a beta of -0.10.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.21). The firm had revenue of $1.43 million during the quarter, compared to analysts’ expectations of $1.97 million. Research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).